Frost & Sullivan officially releases the 'White Paper on the Repair of Damaged Human Type III Collagen by Reconstructive Human Scaffolds'

The 'White Paper on the Repair of Damaged Muscles with Recombinant Human Type III Collagen' starts with the definition and function of collagen, introduces the structure and classification of collagen, as well as the characteristics, classification, advantages, expression system, development history of the industry, and relevant industry policies of recombinant type III collagen. It systematically elaborates on the structural features, technical principles, production process, and biological functionality of recombinant human type III collagen 1068, showcases its application prospects in fields such as medical aesthetics, medical devices, and efficacy skincare, and deeply analyzes the important functions of recombinant human type III collagen 1068 in the field of damaged skin repair.

Collagen, also known as collagen polypeptides, is a crucial structural component of the extracellular matrix within tissues in the body. It is distributed throughout all tissues and organs, such as skin, bones, tendons, ligaments, cartilage, etc. Collagen is a structural protein in the extracellular matrix, with its molecules containing at least one structural domain or a triple helix structure composed of alpha chains, known as the collagen domain. Collagen is a natural biological polymer produced by animal fibroblasts and accounts for one-third of the total protein content in mammals. It is widely present in all tissues and organs, providing strength, durability, and flexibility to tissues. Due to its low immunogenicity, biocompatibility, hemostatic properties, and biodegradability, collagen has become one of the most widely used protein materials in fields such as biomaterials and regenerative medicine, including artificial skin and collagen sponges.

Type III collagen has a stable triple helix conformation, which is determined by its specific amino acid sequence and has a significant impact on its biological functions. In 1971, Miler et al. first identified and described type III collagen. Since then, research on the structure, distribution, function, and preparation of type III collagen has continued to deepen, and the development of recombinant collagen preparation processes has further expanded the application scenarios of type III collagen. Type III collagen is the main structural component of hollow organs such as large blood vessels, uterus, and intestines, which must be able to withstand stretching. It also coexists with other types of collagen such as type I collagen in many other tissues.

Data source: Literature search, Frost & Sullivan analysis

Wound healing involves four stages: hemostasis, inflammation, proliferation, and remodeling. Type III collagen plays an important role in each stage, ultimately restoring the wound to its normal physiological state.

Recombinant type III collagen is obtained by genetically engineering techniques, which involve introducing the coding gene for human type III collagen into host cells. The collagen is then expressed, extracted, and purified. Due to the lack of specific classification standards for recombinant type III collagen, it is usually classified according to the general classification methods for recombinant collagen. According to the 'Guiding Principles for the Naming of Biomaterials Containing Recombinant Collagen' issued by the National Medical Products Administration, recombinant collagen can be divided into the following three categories:

The development process of recombinant human type III collagen reflects the interaction between technological progress and market demand. From theoretical exploration in early academic research to technological breakthroughs in industrial production, and then to widespread application in fields such as medicine and cosmetology, the industry has gone through stages of germination, startup, and rapid development. With the establishment of industry standards and the improvement of regulatory systems, the safety and effectiveness of recombinant human type III collagen products have been continuously verified, laying a solid foundation for future development.

In recent years, with the widespread application of recombinant collagen in medical devices and cosmetics, China has successively formulated and issued multiple industry standards to regulate product quality and ensure consumer safety. In the field of medical devices, the "Recombinant Collagen" (YY/T 1849-2022) issued in 2022 clarified the quality control requirements, testing indicators, and methods for recombinant collagen as raw materials for medical devices, providing a unified technical basis for the industry. Subsequently, the implementation of the "Recombinant Humanized Collagen" (YY/T 1888-2023) in 2023 further refined the quality standards, covering technical requirements, testing methods, biological evaluation, and stability testing, to ensure the safety and effectiveness of products. In the field of cosmetics, the "Recombinant Collagen Raw Materials for Cosmetics" (T/ZGKSL004-2023) issued in April 2023 filled a standard gap in the cosmetics industry and clarified the basic information, testing items, toxicological evaluation, packaging, and transportation requirements for recombinant collagen raw materials used in cosmetics. The introduction and implementation of these industry standards have not only improved the quality management level of domestic recombinant collagen products but also provided important support for the standardized development of the industrial chain.

Recombinant human type III collagen 1068 is a human sequence peptide chain composed of 1,068 amino acids. This characteristic makes it homologous to the natural gene protein sequence of the human body and retains nearly 200 functional domains intact. Its molecular weight is about 130,000 daltons, highly similar to natural human collagen, and possesses good biological activity and human compatibility.

Recombinant human type III collagen 1068 has good biocompatibility and bioactivity, playing a role at different stages of wound repair and having a positive impact on wound healing and skin barrier repair. As a key component of the extracellular matrix, collagen can connect broken collagen fibers, fill interstitial gaps, enhance the supporting structures between cells, rapidly reconstruct skin barrier functions, and restore normal skin conditions; it can activate signaling pathways, promote the proliferation and migration of fibroblasts and the generation of epidermal cells; it prompts fibroblasts to secrete matrix components, enhances tissue toughness and stability, and reduces the risk of scar hyperplasia; it regulates inflammatory cells and inhibits inflammatory mediators, reducing the damage to wounds caused by excessive inflammation, and synergistically improves the quality of wound healing through multiple mechanisms.

In the field of dermatological treatment, recombinant collagen dressings demonstrate their unique advantages and broad application prospects. They play a distinctive role in the treatment of various skin problems such as dermatitis, eczema, acne, post-acne scars, pigmentation, enlarged pores, and burns. The medical recombinant human type III collagen 1068 dressing, as a Class II medical device, is suitable for the care of non-chronic wounds (such as skin barrier damage caused by facial acne) and surrounding skin. It plays an important role in the treatment of various skin problems such as acne, dermatitis, and eczema. Moreover, unlike Class I medical devices like cold compresses and ordinary cosmetic-grade masks, it is safer and more effective.

The type III collagen in medical recombinant human type III collagen dressings can adhere to exposed skin wounds, providing effective protection for the wounds. It also blocks external environmental interference with wound repair, making it suitable for conditions such as seasonal allergies and dermatitis. Its characteristics include: promoting cell proliferation and differentiation, aiding in the repair and regeneration of damaged skin cells; being able to lock in moisture, maintaining skin hydration and providing a moisturizing effect; regulating inflammatory responses, reducing skin inflammation, and alleviating symptoms such as redness, swelling, and itching.

Recombinant human type III collagen has become an important ingredient in the field of efficacy skincare. It closely mimics the structure and function of human type III collagen, promoting skin cell metabolism, accelerating wound healing, and reducing the risk of scar formation. Recombinant collagen forms a stable fiber network structure in the dermis, providing support for the skin, increasing elasticity, reducing wrinkles, and enhancing skin elasticity and luster; it maintains the integrity of the skin barrier, strengthens resistance, and reduces the incidence of problems such as allergies and inflammation.

In addition to being used in medical aesthetics, skin problem treatment, and efficacy skincare, recombinant collagen has also been applied in other medical or consumer fields. Other potential applications of recombinant collagen in the medical field include: heart health and repair, uterine/vaginal repair and regeneration, bladder and urinary system regeneration, periosteum and bone tissue repair, support structures for soft tissues and organs, artificial corneas, etc. In other consumer fields, recombinant collagen can be used in health foods, skincare products, pet products, etc. The mildness and efficiency of recombinant collagen products make it a choice for consumers seeking a high-quality life.

Domekang (Beijing) Biomedical Co., Ltd. focuses on the research, development, and industrialization of recombinant human collagen technology. Through genetic recombination engineering and fermentation engineering, it has constructed a R&D system and production system centered on synthetic biology recombinant human collagen. With the professional academic guidance of benchmark tertiary hospitals, it has deeply penetrated the Chinese skin market, gradually expanded product application areas, and become a third-generation 'recombinant human collagen' high-tech biomedical enterprise in the fields of skin mucosal barrier repair dressings, efficacy skincare products, wound repair new materials, medical aesthetics anti-aging new materials, and regenerative medicine new materials.